JPWO2021119429A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021119429A5 JPWO2021119429A5 JP2022535518A JP2022535518A JPWO2021119429A5 JP WO2021119429 A5 JPWO2021119429 A5 JP WO2021119429A5 JP 2022535518 A JP2022535518 A JP 2022535518A JP 2022535518 A JP2022535518 A JP 2022535518A JP WO2021119429 A5 JPWO2021119429 A5 JP WO2021119429A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- fusion protein
- antibody
- seq
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962947686P | 2019-12-13 | 2019-12-13 | |
| US62/947,686 | 2019-12-13 | ||
| PCT/US2020/064515 WO2021119429A1 (en) | 2019-12-13 | 2020-12-11 | Novel interleukin-15 (il-15) fusion proteins and uses thereof |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023506452A JP2023506452A (ja) | 2023-02-16 |
| JP2023506452A5 JP2023506452A5 (https=) | 2023-12-19 |
| JPWO2021119429A5 true JPWO2021119429A5 (https=) | 2023-12-19 |
| JP7807076B2 JP7807076B2 (ja) | 2026-01-27 |
Family
ID=76330576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022535518A Active JP7807076B2 (ja) | 2019-12-13 | 2020-12-11 | 新規インターロイキン－１５（ｉｌ－１５）融合タンパク質およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230048046A1 (https=) |
| EP (2) | EP4461750A3 (https=) |
| JP (1) | JP7807076B2 (https=) |
| KR (1) | KR20220114063A (https=) |
| CN (1) | CN115087464B (https=) |
| AU (1) | AU2020402097A1 (https=) |
| CA (1) | CA3164337A1 (https=) |
| WO (1) | WO2021119429A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| CA3097625A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof |
| KR20210003813A (ko) | 2018-04-18 | 2021-01-12 | 젠코어 인코포레이티드 | IL-15/IL-15Rα Fc-융합 단백질 및 LAG-3 항원 결합 도메인을 함유하는 LAG-3 표적화 이종이량체 융합 단백질 |
| CN120463822A (zh) | 2018-09-27 | 2025-08-12 | 西里欧发展公司 | 掩蔽型细胞因子多肽 |
| CN113438961A (zh) | 2018-12-20 | 2021-09-24 | Xencor股份有限公司 | 含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白 |
| CN111423510B (zh) * | 2019-01-10 | 2024-02-06 | 迈威(上海)生物科技股份有限公司 | 重组抗人pd-1抗体及其应用 |
| TW202128757A (zh) | 2019-10-11 | 2021-08-01 | 美商建南德克公司 | 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白 |
| WO2022012428A1 (zh) * | 2020-07-14 | 2022-01-20 | 迈威(上海)生物科技股份有限公司 | 抗pd-1抗体及其稳定制剂 |
| WO2022115865A2 (en) | 2020-11-25 | 2022-06-02 | Xilio Development, Inc. | Tumor-specific cleavable linkers |
| CN116655771A (zh) * | 2021-05-28 | 2023-08-29 | 苏州复融生物技术有限公司 | 一种新型白介素15突变体多肽的开发及其应用 |
| KR20240055714A (ko) * | 2021-07-09 | 2024-04-29 | 레전드 바이오테크 아일랜드 리미티드 | 돌연변이 il-15 조성물 및 이의 방법 |
| WO2023048518A1 (ko) * | 2021-09-24 | 2023-03-30 | 바이오엔시스템스 주식회사 | Pd-1 및 il-15를 포함하는 융합단백질 이량체 및 이의 용도 |
| WO2023133424A2 (en) * | 2022-01-05 | 2023-07-13 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins and anti-pd-1 fusion peptides |
| JP2025507733A (ja) * | 2022-02-28 | 2025-03-21 | ウーシー バイオロジクス アイルランド リミテッド | Ｉｌ－１５変異体を含むヘテロ二量体ポリペプチド錯体とその使用 |
| US20240025968A1 (en) * | 2022-04-07 | 2024-01-25 | Xencor, Inc. | LAG-3 TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND LAG-3 ANTIGEN BINDING DOMAINS |
| CN116854821A (zh) * | 2022-08-15 | 2023-10-10 | 海徕科(北京)生物技术有限公司 | IL-15突变体-Fc/IL-15Rα亚基-Fc异源二聚体及其用途 |
| CN116063512B (zh) * | 2022-10-13 | 2025-11-07 | 深圳市百士通科技开发有限公司 | 多功能重组抗体及其制备方法和应用 |
| EP4562059A1 (en) * | 2023-02-21 | 2025-06-04 | RemeGen Co., Ltd. | Il-15 agonists for cancer |
| WO2024249568A1 (en) | 2023-05-30 | 2024-12-05 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
| CN121889424A (zh) | 2023-08-14 | 2026-04-17 | 派拉冈医疗公司 | α4β7整联蛋白结合蛋白及使用方法 |
| WO2025252855A1 (en) * | 2024-06-05 | 2025-12-11 | Institut National de la Santé et de la Recherche Médicale | IL-15 MUTEINS WITH PH-DEPENDENT BINDING FOR IL-15Rbeta |
| CN118995825B (zh) * | 2024-10-24 | 2025-02-07 | 星奕昂(上海)生物科技有限公司 | 一种特异性定量标定白细胞介素15活性的细胞系及其应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| HU230769B1 (hu) | 1999-01-15 | 2018-03-28 | Genentech Inc. | Módosított effektor-funkciójú polipeptid-változatok |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| US20060236411A1 (en) * | 2002-10-14 | 2006-10-19 | Ingeborg Dreher | Antagonists il-15 |
| CN103405405A (zh) | 2002-12-09 | 2013-11-27 | 阿布拉西斯生物科学有限责任公司 | 组合物和传递药剂的方法 |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| EA201000910A1 (ru) | 2007-11-30 | 2011-04-29 | Бристоль-Мейерз Сквибб Компани | Конъюгат "моноклональное антитело против в7н4/лекарственное средство" и способы его применения |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| NZ592420A (en) * | 2008-10-02 | 2012-12-21 | Emergent Product Dev Seattle | Cd86 antagonist multi-target binding proteins |
| CN102762593B (zh) | 2009-07-31 | 2015-05-20 | 梅达雷克斯有限责任公司 | 抗btla的完全人抗体 |
| PH12012501751A1 (en) | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| WO2011155607A1 (ja) | 2010-06-11 | 2011-12-15 | 協和発酵キリン株式会社 | 抗ｔｉｍ－３抗体 |
| NZ630790A (en) * | 2012-10-24 | 2016-11-25 | Admune Therapeutics Llc | Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes |
| RU2689717C2 (ru) * | 2014-01-08 | 2019-05-28 | Шанхай Хэнжуй Фармасьютикал Ко., Лтд. | Гетеродимерный белок il-15 и его применения |
| EP3350205A1 (en) * | 2015-09-16 | 2018-07-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Specific interleukin-15 (il-15) antagonist polypeptide and uses thereof for the treatment of inflammatory and auto-immune diseases |
| AR108468A1 (es) * | 2016-05-13 | 2018-08-22 | Medimmune Llc | POLIPÉPTIDOS DE FUSIÓN CD40L-Fc Y MÉTODOS DE USO DE LOS MISMOS |
| CN110214147A (zh) * | 2016-10-14 | 2019-09-06 | Xencor股份有限公司 | IL15/IL15Rα异源二聚体FC-融合蛋白 |
| US11084863B2 (en) * | 2017-06-30 | 2021-08-10 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains |
| EP3727146A4 (en) * | 2017-12-19 | 2021-10-06 | Blaze Bioscience, Inc. | TUMOR HOMING AND CELL-PENETANT PEPTIDE IMMUNO-ONCOLOGY AGENT COMPLEX AND METHOD OF USE |
| CA3091857A1 (en) * | 2018-02-26 | 2019-08-29 | Synthorx, Inc. | Il-15 conjugates and uses thereof |
| JP2021514625A (ja) * | 2018-03-01 | 2021-06-17 | グリコトープ ゲーエムベーハー | 抗ｍｕｃ１抗体およびｉｌ−１５を含む融合タンパク質構築物 |
| CA3097625A1 (en) * | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof |
| EP3810171B1 (en) * | 2018-06-22 | 2025-07-09 | Cugene Inc. | Novel interleukin-15 (1l-15) fusion proteins and uses thereof |
| AU2019359475A1 (en) * | 2018-10-12 | 2021-05-20 | Xencor, Inc. | PD-1 targeted IL-15/IL-15Ralpha Fc fusion proteins and uses in combination therapies thereof |
| MX2022007202A (es) * | 2019-12-13 | 2022-10-07 | Cugene Inc | Fármacos bioactivables a base de citocinas y metodos de uso de los mismos. |
-
2020
- 2020-12-11 JP JP2022535518A patent/JP7807076B2/ja active Active
- 2020-12-11 KR KR1020227024241A patent/KR20220114063A/ko active Pending
- 2020-12-11 AU AU2020402097A patent/AU2020402097A1/en active Pending
- 2020-12-11 CN CN202080096546.5A patent/CN115087464B/zh active Active
- 2020-12-11 EP EP24191000.9A patent/EP4461750A3/en active Pending
- 2020-12-11 US US17/784,186 patent/US20230048046A1/en active Pending
- 2020-12-11 WO PCT/US2020/064515 patent/WO2021119429A1/en not_active Ceased
- 2020-12-11 EP EP20899197.6A patent/EP4072588A4/en not_active Withdrawn
- 2020-12-11 CA CA3164337A patent/CA3164337A1/en active Pending